Find company announcements below, or check out the latest news in the right side menu.
17. April 2007
Novozymes A/S will receive a total settlement of USD 15.3 million in connection with the termination of the US patent infringement suit against Danisco A/S.
3. April 2007
The new business area is named Biopharmaceutical Ingredients, and will comprise the activities related to Novozymes Delta, Novozymes GroPep, Novozymes Biopharma and also the research project within recombinant human serum albumin (rHSA).
9. March 2007
The Annual Meeting of Shareholders in Novozymes A/S took place yesterday, with the report on the company’s activities in the last financial year being adopted.
2. March 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B
28. February 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transaction under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
19. February 2007
Novozymes A/S (Bagsvaerd, Denmark) awarded double damages, attorneys' fees and costs. Danisco found to have wilfully infringed Novozymes' patent.
14. February 2007
In accordance with Section 28a of the Danish Securities Trading Act, Novozymes reports the following transactions under ISIN DK0010272129, Novozymes B shares under the symbol NZYM B.
12. February 2007
9. February 2007
5. February 2007
1. February 2007
31. January 2007
25. January 2007
2006 was a very satisfactory year for Novozymes. Growth of 11% in earnings, 8% in sales and free cash flow of DKK 1,058 million were fully in line with the outlook. Growth is expected to continue in 2007.
12. December 2006
Novozymes A/S has completed the acquisition of Australian company GroPep Ltd with effect from December 12, 2006.
7. December 2006
We are pleased to announce that the Board of Directors has approved the appointment of Benny D. Loft as the new Executive Vice President and Chief Financial Officer of Novozymes, replacing Per Månsson, who died on November 17.
27. November 2006
Novozymes announces that all conditions for the completion of the acquisition of GroPep Ltd. have now been fulfilled. The transaction is expected to close on December 12, 2006.
20. November 2006
It is with our deepest regret that we have to announce that Novozymes´ Executive Vice President and Chief Financial Officer, Per Månsson after a short period of illness passed away last Friday.
25. October 2006
The results for the first nine months of 2006 are highly satisfactory. Growth in operating profit and sales of 11% and 8% respectively is wholly in line with the company’s outlook. The financial outlook for 2006 is being adjusted upwards.
25. August 2006
22. August 2006
Denmark – Novozymes has today acquired 600,000 B shares, worth DKK 241.3 million, from Novo A/S. The transaction price is DKK 402.16 per share and has been calculated as the average market price from August 9, 2006 to August 22, 2006 in the open window, fol
14. August 2006
Novozymes takes another important step to become a leading supplier of recombinant ingredients for the biopharmaceutical industry
8. August 2006
Novozymes maintains the high earnings level. Growth in sales and operating profit of 8% and 10% respectively for the first half of 2006 is in line with the company’s outlook.
6. July 2006
As of July 6, 2006 Novozymes has completed the acquisition of Delta Biotechnology Ltd. from the Sanofi- Aventis group.
13. June 2006
Bagsvaerd – Novozymes has completed a reduction of its share capital as decided and approved at Novozymes A/S’ annual general meeting on March 1, 2006.
25. April 2013
1. April 2013
| Copyright © 2010 Novozymes. All Rights Reserved.